Indole Compounds Targeting the AR BF3 Site Against Drug Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-androgen drugs target the ligand-binding site of the androgen receptor (AR) indirectly, leading to resistance and progression of prostate cancer, and there is no effective treatment for Kennedy's disease caused by androgen receptor disruptions.
Innovation Solution
Development of compounds that directly modulate the androgen receptor's Binding Function-3 (BF3) site, inhibiting AR activity through allosteric modification, thereby preventing co-activator interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-androgen drugs target the ligand-binding site of the androgen receptor, then AR activity is inhibited, but drug resistance develops and disease progresses
Solution Approach 1:
The patent introduces an intermediary approach by targeting the BF3 site as a mediator between the androgen receptor and co-activators. Instead of directly blocking the ligand-binding site, the compounds act as intermediaries that prevent co-activator recruitment through BF3 site binding, thereby inhibiting AR transcriptional activity through a different mechanism that bypasses conventional resistance pathways
Solution Approach 2:
The invention changes the target parameter from the ligand-binding site to the Binding Function-3 site on the androgen receptor. This parameter change represents a fundamental shift in the molecular target, moving from preventing ligand binding to blocking co-activator interaction at the BF3 site, which alters the mechanism of action and overcomes resistance to traditional anti-androgens
2Reliability
If androgen receptor activity is blocked to treat prostate cancer, then cancer progression is inhibited, but Kennedy's disease lacks effective treatment options
Solution Approach 1:
The patent achieves universality by developing compounds that can treat multiple conditions through a common mechanism. The BF3 site-targeting compounds serve multiple functions: they inhibit AR activity in prostate cancer while also addressing Kennedy's disease caused by AR disruptions, demonstrating multi-functionality across different pathological conditions involving androgen receptor dysregulation
3Reliability
If compounds directly modulate the BF3 site to inhibit AR activity, then co-activator interactions are prevented, but new compounds must be developed
Solution Approach 1:
The patent applies segmentation by dividing the androgen receptor functional domains into distinct targetable regions. By focusing specifically on the BF3 site as a separate functional element from the ligand-binding site, the invention enables independent targeting and modulation of this specific domain, allowing for targeted compound design that addresses AR activity through a segmented approach to receptor function
Data Source
AI summary
Provided herein are indole compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.